Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
AssigneesIsis Pharmaceuticals, Inc., Boehrinber Ingelheim Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Takashi Kei Kishimoto
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of modulating the shedding of L-selectin in cells or tissues using an inhibitor of TACE expression or activity. Antisense oligonucleotides targeted to nucleic acids encoding TACE are preferred forms of TACE inhibitors. These methods are believed to be useful both therapeutically and diagnostically and as research tools. The present invention further comprises methods of treating conditions associated with altered L-selectin shedding or altered L-selectin levels.
Claims20
A method of inhibiting L-selectin shedding in cells or tissue comprising contacting said cells or tissue in vitro with an antisense compound 8 to 30 nucleotides in length targeted to a 3′ untranslated region, or a stop codon region of a nucleic acid molecule encoding human TNF-α converting enzyme, wherein said antisense compound inhibits human TNF-α converting enzyme expression or activity.
An antisense compound lip to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 8, 9, 10 or 11 wherein said antisense compound inhibits TNF-α converting enzyme expression or activity.
Dependencies are inferred from the claim text.